NXTC: NextCure Inc. filed SEC Form 8-K: Leadership Update
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NXTC
Across the 16 sessions after earlier NXTC headlines, the stock closed higher 7 times and lower 9 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NXTC | SPY |
|---|---|---|---|
| Aug 10, 2026 | Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 | +17.1% | -0.0% |
| Aug 7, 2026 | NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results | +4.5% | +0.6% |
| Jun 4, 2026 | NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers | +1.3% | +0.4% |
| Jun 1, 2026 | NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 | -45.5% | +0.3% |
| May 8, 2026 | NextCure Provides Business Update and Reports First Quarter 2026 Financial Results | -4.1% | +0.8% |
| May 4, 2026 | NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers | -4.7% | -0.4% |
Quantisnow market dataNASDAQ
NXTC
NextCure Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Get push alerts for NXTC
Full NXTC profile on Quantisnow Follow NXTC and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time